-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-502254-13-00
5
2023-12-18
Oligoprogressive metastatic castration-refractory prostate cancer
-
2023-503671-16-00
6
2023-12-15
Periodontitis
-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2022-502021-18-00
6
2023-10-12
Rheumatoid Arthritis
-
2022-502281-25-00
5
2023-09-27
Focal Onset Seizures
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-504973-19-01
5
2023-09-06
early-stage, intermediate-risk cervical cancer
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-502732-39-00
10
2023-09-01
Previously treated non-ocular advanced melanoma
-
2023-504999-25-00
5
2023-07-14
Acute Myeloid Leukemia
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2023-507171-22-00
9
2023-06-21
Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-508227-13-00
7
2023-06-19
Advanced solid tumors
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2023-504897-39-00
1
2023-04-13
Advanced or refractory solid tumours (Part 1)
-
2023-503481-23-00
5
2023-03-20
Maintenance treatment in metastatic non-squamous lung cancer
-
2022-501181-22-01
4
2023-02-06
Pancreatic adenocarcinoma
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2023-506239-14-00
5
2022-12-13
Crohn’s Disease
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria